Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,181.0
-17.6 (-0.55%)

 

  • STI Straits Times Index
    3,181.0
    -17.6 (-0.55%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,531.2
    -3.8 (-0.25%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,308.8
    -300.3 (-1.09%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,039.7
    9.5 (0.31%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,386.7
    -92.4 (-0.39%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,882.3
    -60.2 (-1.01%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,078.9M
  • Value: 1,171.0M
  • Rise: 88
  • Fall: 225
  • Unch: 501

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AusGroup^0.048-0.004
Rex Intl0.193-0.007
Ntegrator Intl0.008-0.002
Medtecs Intl0.097+0.001
Ley Choon0.019+0.001
YZJ Shipbldg SGD1.040-
Singtel3.100-0.030
ComfortDelGro2.020-0.030
Genting Sing0.880-
Dyna-Mac0.134-0.016

World Indices

World Indices
Name Last Change
Nasdaq 9,576.6 -174.4
HSI 27,308.8 -300.4
HSCEI 10,790.8 -123.1
Jakarta 5,882.3 -60.2
Nikkei 225 23,386.7 -92.4
SSE Comp 3,039.7 +9.5
Shanghai A 3,185.3 +10.0
Shanghai B 244.9 +0.8
KOSPI 2,162.8 -32.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

AGILENT TECHNOLOGIES INC AGILENT TECHNOLOGIES
Updated on 21 Feb 2020 (End of trading day)
Last (USD): 85.070 Change: +0.730 High: 85.090 Remarks: -
Change (%): +0.87 Low: 83.403
Open 83.900 Yesterday's Close 84.33999999999999
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 1,762,536 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 1.01684 Trailing EPS (USD) e 2.45843 NAV (USD) b 15.6001
PE a 83.661 Trailing PE f 34.603 Price / NAV b 5.4532
Dividend (USD) d 0.609870 Cash In Hand (USD) g 3.9451 Issued & Paid-up Shares c 310,768,000
Dividend Yield (%) d 0.717 Price / Cash In Hand g 21.563 Treasury Shares h -
Beta - 75 Daysi 1.382 R-Squared - 75 Days(%)i 41.57 Market Cap (M) 26,437.034
Beta - 500 Daysi 1.037 R-Squared - 500 Days (%)i 26.69 Enterprise Value (M) 27,673.034
Piotroski F Score 7 Exchange Code A Par Value ( $ ) n.a.
52 Weeks Volatility (%) 22.71 Free Float (%) 99.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 11 Feb 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 03 Sep 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference AGILENT TECHNOLOGIES INC NYSE 26,437.034 83.661 34.603 5.4532 0.717
Industry Biotechnology NYSE 5,429.571 18291.650 93.962 6.3967 0.582
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 3,409.098 54.371 62.438 3.1319 -
Local Peer MYOVANT SCIENCES LTD NYSE 1,020.890 - - -20.8815 -
Local Peer KADMON HLDGS INC NYSE 809.126 - - 21.1779 -
Local Peer ARCUS BIOSCIENCES INC NYSE 794.278 - - 4.4817 -
Local Peer ENZO BIOCHEM INC NYSE 107.003 42.988 130.174 1.3661 -
Global Peer AMGEN INC NASDAQ 131,403.102 15.654 16.756 13.5845 2.530
Global Peer CSL ASX 152,685.905 56.910 52.709 - 0.789
Global Peer GILEAD SCIENCES INC NASDAQ 88,240.200 16.176 16.383 3.8958 3.313
Global Peer AMGEN-T HKEx 589,807.000 8.965 9.598 7.8255 4.417
Global Peer VERTEX PHARMACEUTICAL NASDAQ 63,855.362 30.460 54.261 10.4935 -
Global Peer BIOGEN INC NASDAQ 58,609.089 13.228 9.953 4.3924 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 44,354.551 18.145 20.963 3.9996 -
Global Peer ILLUMINA INC NASDAQ 43,503.180 52.667 43.416 9.4305 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 22,835.299 294.265 9.498 2.0259 -
Global Peer SEATTLE GENETICS INC NASDAQ 20,154.420 - - 10.7416 -
Other Global Peers WUXI BIO (HKEx), SINO BIOPHARM (HKEx), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), Lonza (SGX), GENSCRIPT BIO (HKEx), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), 3SBIO (HKEx), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ALKERMES PLC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), INSMED INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ALECTOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALPHAMAB-B (HKEx), EPIZYME INC (NASDAQ), VIELA BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), ARVINAS INC (NASDAQ), REGENXBIO INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), HAOHAI BIOTEC (HKEx), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MYRIAD GENETICS INC (NASDAQ), POLYNOVO LIMITED (ASX), NEXTCURE INC (NASDAQ), FRONTAGE (HKEx), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), AVITA MEDICAL LTD (ASX), ENANTA PHARMACEUTICALS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), IMMUNOGEN INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), AVROBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), PRECIGEN INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), RETROPHIN INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ASCENTAGE-B (HKEx), BIOXCEL THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ARDELYX INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), COMPUGEN (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ASCLETIS-B (HKEx), NANTKWEST INC (NASDAQ), MACROGENICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MERUS B V (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), SINOMAB BIO-B (HKEx), AGENUS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROTHENA CORP PLC (NASDAQ), TRANSLATE BIO INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), ESSEX BIO-TECH (HKEx), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), LEE'S PHARM (HKEx), SPECTRUM PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PFENEX INC (NYSE American), UNITY BIOTECHNOLOGY INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TELIX PHARMACEUTIC (ASX), KAMADA (NASDAQ), SERES THERAPEUTICS (NASDAQ), DPHARMA (Bursa), VBI VACCINES INC CDA (NASDAQ), GERON CORP (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), XOMA CORP (NASDAQ), BBI LIFE SCI (HKEx), LIMINAL BIOSCIENCES INC (NASDAQ), IMV INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), NEXT SCIENCE LTD (ASX), LA JOLLA PHARMACEUTICAL CO (NASDAQ), MEDICINOVA INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), PIERIS PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), GLYCOMIMETICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), VERASTEM INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), CEL-SCI CORP (NYSE American), SOLID BIOSCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ARAVIVE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), UNI-BIO GROUP (HKEx), AVALON GLOBOCARE CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SAVARA INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), OTONOMY INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), SURFACE ONCOLOGY INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), IMUGENE LIMITED (ASX), 22ND CENTURY GROUP INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), SYNLOGIC INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), VACCINEX INC (NASDAQ), EQUILLIUM INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), ORGENESIS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), LEAP THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INMUNE BIO INC (NASDAQ), RESTORBIO INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CT ENTERPRISE (HKEx), OPIANT PHARMACEUTICALS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VAXART INC (NASDAQ), BIOTRON (ASX), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ZAFGEN INC (NASDAQ), CURIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), TOCAGEN INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), T2 BIOSYSTEMS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), EVOGENE LTD (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), SEELOS THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ALIMERA SCIENCES INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), MEMPHASYS LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ORAGENICS INC (NYSE American), BIOCARDIA INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), ANTEOTECH LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), IBIO INC (NYSE American), REGENT PACIFIC (HKEx), OCUGEN INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), AZURRX BIOPHARMA INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), BIONOMICS LTD (ASX), CLEVELAND BIOLABS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), APTEVO THERAPEUTICS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CELLECTAR BIOSCIENCES INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), HEAT BIOLOGICS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), PRECIPIO INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), Suntar Eco-City^ (SGX), CYCLACEL PHARMA IN (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), REGENEUS LTD (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), ADALTA LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), HAO WEN HLDGS (HKEx), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), PHIO PHARMACEUTICALS CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), LEAF RESOURCES LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), CRYOSITE (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.750
-0.87 %
10 Days -+1.900
+2.28 %
20 Days --3.190
-3.61 %
Medium Term Return 3 Months 0.180+5.950
+7.75 %
6 Months 0.344+15.520
+22.81 %
1 Year 0.672+6.650
+9.34 %
Long Term Return 2 Years 1.283+14.370
+22.14 %
3 Years 1.828+33.330
+67.95 %
5 Years 2.720+42.860
+107.98 %
Annualised Return Annualised --
+15.77 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 65.350 - 90.640 Change From 1 Year Low +19.720 % Change From 1 Year Low (%) +30.18
Change From 1 Year High -5.570 % Change From 1 Year High (%) -6.15
2 Years Range 60.420 - 90.640 Change From 2 Years Low +24.650 % Change From 2 Years Low (%) +40.80
Change From 2 Years High -5.570 % Change From 2 Years High (%) -6.15
5 Years Range 33.115 - 90.640 Change From 5 Years Low +51.955 % Change From 5 Years Low (%) +156.89
Change From 5 Years High -5.570 % Change From 5 Years High (%) -6.15
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Feb 2020 83.900 85.090 83.403 85.070 1,762,536 -
20 Feb 2020 84.900 84.990 83.360 84.340 2,543,584 -
19 Feb 2020 84.700 85.840 83.450 85.350 4,741,298 -
18 Feb 2020 85.660 86.080 84.530 84.790 2,872,477 -
14 Feb 2020 85.720 85.860 85.115 85.820 1,965,354 -
13 Feb 2020 85.100 85.680 84.660 85.470 1,596,270 -
12 Feb 2020 85.400 86.060 85.290 85.430 1,464,199 -
11 Feb 2020 85.030 85.670 84.840 85.090 1,543,151 -
10 Feb 2020 83.040 84.635 82.925 84.430 2,066,861 -
07 Feb 2020 84.610 84.790 82.920 83.170 1,447,606 -
06 Feb 2020 85.310 85.390 84.580 84.820 835,477 -
05 Feb 2020 84.530 85.500 84.390 84.930 2,345,127 -
04 Feb 2020 82.850 83.900 82.780 83.520 1,676,020 -
03 Feb 2020 83.290 83.690 82.110 82.150 1,919,771 -
31 Jan 2020 84.030 84.335 82.340 82.560 2,850,446 -
30 Jan 2020 84.900 85.030 83.600 84.380 3,026,658 -
29 Jan 2020 87.550 88.360 87.150 87.240 1,131,523 -
28 Jan 2020 86.850 87.480 86.190 87.180 1,652,210 -
27 Jan 2020 86.540 87.170 86.210 86.560 1,867,959 -
24 Jan 2020 89.450 89.460 87.580 88.260 1,164,489 -
23 Jan 2020 89.620 89.980 88.660 89.070 1,228,291 -
22 Jan 2020 89.940 90.640 89.842 90.130 1,665,767 -
Summary
Current 2 Weeks
(07 Feb 2020 to 21 Feb 2020)
84.610 86.080 82.920 85.070 22,003,336 -
Previous 2 Weeks
(24 Jan 2020 to 06 Feb 2020)
89.450 89.460 82.920 84.820 18,469,680 -
4 Weeks from
(24 Dec 2019 to 23 Jan 2020)
85.450 86.080 82.920 89.070 30,737,661 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.